

Maria Giovanna Lupo

Maria Giovanna Lupo graduated from University of Padua, Italy, with a B.Sc and a M.Sc in Molecular Biology (2013 and 2016, respectively). She received her Ph.D at the same University in 2021 in Pharmaceutical Sciences, doing research in Cardiovascular Pharmacology and Biology, mainly studying proprotein convertase subtilisin/kexin type 9 (PCSK9), a modulator of low-density lipoprotein receptor (LDLR).

In particular, she focussed on *i)* unravelling the role of PCSK9 in the onset and progression of vascular calcification secondary to renal impairment, using both *in vitro* and *in vivo* systems, *ii)* cell-based screening of innovative natural compounds as potential lipid-lowering agents able to interfere with PCSK9 activity, *iii)* *in vivo* testing of new pharmaceutical preparations of well-established hypolipidemic nutraceuticals (such as berberine), *iv)* measuring PCSK9 plasma levels for clinical purpose.

At the present, she is a PostDoc researcher fellow at the Dept. of Pharmaceutical and Pharmacological Sciences (University of Padua), broadening her interest in the role of PCSK9 in modulating insulin-resistance, ectopic fat accumulation and low-grade inflammation.

To date, Dr Lupo co-authored 29 publications (Scopus indices: 284 citations, H-index 9).

Padua, 27th August 2021.